MENU
AUTL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Autolus Therapeutics (AUTL) Ownership - Who owns Autolus Therapeutics?
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
191 Wood Lane
Phone
+44 2038296230
Employees
471
Web
https://www.autolus.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
550.91M
P/E Ratio
N/A
Total Cash
516.58M
Projected Growth
N/A
Total Debt
57.71M
Revenue
9.01M
Risk (Beta)
2.24
Dividend Yield
N/A
Total Cash/Share
1.94
Total Debt/Equity
N/A
Revenue/Share
0.03 USD as % of share price
Fundamentals
AUTL
Capitalization
551M
P/E Ratio
N/A
Risk (Beta)
2.24
Dividend Yield
N/A
Total Cash
517M
Total Cash/Share
1.94
Total Debt
57.7M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.03%
Revenue
9.01M
ROE
N/A
Book Value
371M
P/B Ratio
1.48
Cash Flow
N/A
Earnings
-0.88
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
12K
Current Ratio
9.24
Current Revenue Per Employee
13882.53
Dividends Per Share - Security
N/A
EBITDA
-226.02M
Float
N/A
Float - Current
N/A
Gross Income Margin
-99.86
Revenue To Assets
-28.90
Shares Held By Institutions
509M
Shares Outstanding - Current
266M
Total Liabilities
375M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-18.723
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of cancer treatments
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
191 Wood Lane
Phone
+44 2038296230
Employees
471
Web
https://www.autolus.com